Screening for sensitivity towards vincristine and doxorubicin in a newly established B-cell cancer cell line panel revealed great variability in the dose resulting in 50% growth inhibition (GI50)
Publikation: Konferencebidrag › Konferenceabstrakt til konference › Forskning